107. Juvenile idiopathic arthritis Clinical trials / Disease details
Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04337437 (ClinicalTrials.gov) | April 22, 2019 | 1/4/2020 | Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers | The Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Genakumab for Injection in Chinese Healthy Volunteers | Juvenile Idiopathic Arthritis | Drug: Genakumab;Drug: Placebo for this trial | GeneScience Pharmaceuticals Co., Ltd. | Peking Union Medical College Hospital | Recruiting | 18 Years | 50 Years | All | 40 | Phase 1 | China |